Influence of mutations associated with Gilbert and Crigler-Najjar type II syndromes on the glucuronidation kinetics of bilirubin and other UDP-glucuronosyltransferase 1A substrates.
about
Identification of residues that confer sugar selectivity to UDP-glycosyltransferase 3A (UGT3A) enzymesNew insights in bilirubin metabolism and their clinical implicationsPolymorphic expression of UDP-glucuronosyltransferase UGTlA gene in human colorectal cancerLineage-Specific Changes in Biomarkers in Great Apes and HumansSpectrum of UGT1A1 Variations in Chinese Patients with Crigler-Najjar Syndrome Type IIComparison of the drug-drug interactions potential of erlotinib and gefitinib via inhibition of UDP-glucuronosyltransferases.A humanized UGT1 mouse model expressing the UGT1A1*28 allele for assessing drug clearance by UGT1A1-dependent glucuronidationBilirubin glucuronidation revisited: proper assay conditions to estimate enzyme kinetics with recombinant UGT1A1.Diagnosis and treatment of a 16-year-old Chinese patient with concurrent hereditary hemochromatosis and Gilbert's syndromeCorrelation between bilirubin glucuronidation and estradiol-3-gluronidation in the presence of model UDP-glucuronosyltransferase 1A1 substrates/inhibitors.Apiaceous vegetable consumption decreases PhIP-induced DNA adducts and increases methylated PhIP metabolites in the urine metabolome in rats.A case of concomitant Gilbert's syndrome and hereditary spherocytosis.Drug-Drug Interaction Potentials of Tyrosine Kinase Inhibitors via Inhibition of UDP-Glucuronosyltransferases.Scaling factors for the in vitro-in vivo extrapolation (IV-IVE) of renal drug and xenobiotic glucuronidation clearancePharmacogenetics of Gilbert's syndrome.Distribution of selected gene polymorphisms of UGT1A1 in a Saudi population.Prediction of deleterious non-synonymous single-nucleotide polymorphisms of human uridine diphosphate glucuronosyltransferase genes.UGT1A1 polymorphisms in cancer: impact on irinotecan treatment.Genetic polymorphism in metabolism and host defense enzymes: implications for human health risk assessment.Bilirubin Decreases Macrophage Cholesterol Efflux and ATP-Binding Cassette Transporter A1 Protein Expression.Identification of UDP glycosyltransferase 3A1 as a UDP N-acetylglucosaminyltransferase.Gilbert-Meulengracht's syndrome and pharmacogenetics: is jaundice just the tip of the iceberg?The prediction of drug-glucuronidation parameters in humans: UDP-glucuronosyltransferase enzyme-selective substrate and inhibitor probes for reaction phenotyping and in vitro-in vivo extrapolation of drug clearance and drug-drug interaction potentiaDefective UGT1A1 causes hyperbilirubinemiaDefective UGT1A4 causes hyperbilirubinemiaInhibition of human drug-metabolising cytochrome P450 and UDP-glucuronosyltransferase enzyme activities in vitro by uremic toxins.
P2860
Q24336118-905AB162-404E-4F9D-98BF-7BB742E94A23Q26863145-DE658461-3CEA-428B-81FE-28D7416B6A8AQ28487071-6FD50860-FDDC-44DE-809E-788786F55FA7Q28547060-1B65D1FF-6834-4FE9-B9AC-A7409FB61C4CQ28547377-D9E60843-1442-4196-A73B-024ED9C8DF81Q33574627-4F749C1D-F968-4B3C-B033-E4A483CBDBBAQ33861874-9E2A7CF7-DCAB-44CF-9E8A-BC36547AF18CQ34257505-0D4E9AA1-8069-4F9D-A966-263242FD4381Q34306168-5C97E70D-984D-4E54-9770-C8DC324E4921Q34551930-3261889E-D195-4B88-A78B-EEAF382CD284Q35107855-9AEB1A3D-73AA-4855-BFE4-66FE86FE8F16Q35832977-E7F9B47A-BE2B-47CF-96C8-41A0335C31C4Q36353657-A4243741-609C-4B75-A55B-F8E688FF93E5Q36924729-BC71F8E1-F456-44FF-AC55-7E7299103A90Q37179528-14780177-3AFA-4C6C-84F6-7C0FA106A74FQ37180144-6F148560-D64E-4679-8350-B5E524458E49Q37378051-40E93759-95A4-4D92-8203-99B5EA67149EQ37682812-D0147B16-F5CC-40AA-A3CC-615499E9FB15Q37775981-9A166E8D-3193-4C32-B64C-2388DB942AB6Q38813542-B5FCEF4C-E445-4CF8-8D97-4538B28DD5AEQ39921876-E6C997A9-579C-421C-B3BC-DF3D795040DFQ43195722-FC63F333-C4B6-4A4A-9EFF-95888A3E6C01Q43268650-8412EC3C-2D64-47A9-9488-0994F05F7BA9Q45316497-8804D5CD-7593-4E92-802E-9CF79FAE91E0Q45316498-F8F8F34B-56BD-4C4A-AD79-9C0911C2D244Q47853973-AD5A13DE-C271-4362-86D3-CB7AFB1C1423
P2860
Influence of mutations associated with Gilbert and Crigler-Najjar type II syndromes on the glucuronidation kinetics of bilirubin and other UDP-glucuronosyltransferase 1A substrates.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
Influence of mutations associa ...... osyltransferase 1A substrates.
@en
type
label
Influence of mutations associa ...... osyltransferase 1A substrates.
@en
prefLabel
Influence of mutations associa ...... osyltransferase 1A substrates.
@en
P2093
P1476
Influence of mutations associa ...... nosyltransferase 1A substrates
@en
P2093
David J Elliot
John O Miners
Krongtong Yoovathaworn
Wandee Udomuksorn
P304
P356
10.1097/FPC.0B013E328256B1B6
P577
2007-12-01T00:00:00Z